Intrahepatic cholestasis of pregnancy (ICP) has a complex etiology with a signifi cant genetic component. Heterozygous mutations of canalicular transporters occur in a subset of ICP cases and a population susceptibility allele (p.444A) has been identifi ed in ABCB11 . We sought to expand our knowledge of the detailed genetic contribution to ICP by investigation of common variation around candidate loci with biological plausibility for a role in ICP ( ABCB4 , ABCB11 , ABCC2 , ATP8B1 , NR1H4 , and FGF19) . METHODS: ICP patients ( n = 563) of white western European origin and controls ( n = 642) were analyzed in a casecontrol design. Single-nucleotide polymorphism (SNP) markers ( n = 83) were selected from the HapMap data set (Tagger, Haploview 4. 1 (build 22) ). Genotyping was performed by allelic discrimination assay on a robotic platform. Following quality control, SNP data were analyzed by Armitage ' s trend test.
INTRODUCTION
Intrahepatic cholestasis of pregnancy (ICP), also known as obstetric cholestasis, occurs in ~ 1 in 150 UK pregnancies. Mater-nal symptoms of the disease include pruritus, raised serum bile acids, and deranged liver function tests ( 1 -4 ) . Liver transaminases can be increased as much as 100-fold, but the bilirubin A Comprehensive Analysis of Common Genetic Variation Around Six Candidate Loci for Intrahepatic Cholestasis of Pregnancy level is usually normal or mildly raised. Fetal consequences of ICP include spontaneous and iatrogenic preterm labor, meconium-stained amniotic fl uid, fetal distress, and intrauterine death ( 5 -8 ) . Approximately 80 % of patients present aft er 30 weeks of gestation and diagnosis is routinely confi rmed by elevated serum bile acid concentrations and liver function tests ( 9 ) . Higher levels of fasting and nonfasting serum bile acids ( > 40 μ M ) have been associated with increased risk of adverse pregnancy outcomes including spontaneous preterm labor, meconium passage, stillbirth, and prolonged admission to the neonatal unit ( 8, 10 ) . Severe ICP, defi ned by maternal serum bile acid levels of ≥ 40 μ M , aff ects 1 in 1,000 pregnancies in the United Kingdom ( 10 ) . Treatment is usually with ursodeoxycholic acid, to which ~ 70 % of patients respond with improvement in maternal liver function tests, bile acids, and pruritus ( 11, 12 ) . It is currently not known whether ursodeoxycholic acid treatment reduces the risk of adverse pregnancy outcome, although the results of two recent studies were encouraging ( 12, 13 ) . Th e impact of ICP for the off spring was further highlighted by a recent study that reported increased rates of obesity and dyslipidemia in the 16-year-old off spring of aff ected women ( 14 ) .
ICP has a complex, multifactorial etiology with hormonal, environmental, and genetic infl uences. Considerable evidence for a genetic predisposition to this disease comes from signifi cant familial clustering ( 15, 16 ) , population-specifi c risk diff erences ( 17 ) , and increased risk with an aff ected fi rst-degree relative ( 18 ) . Genes mutated in progressive familial intrahepatic cholestasis (PFIC) and the related condition benign recurrent intrahepatic cholestasis (BRIC), namely ABCB4 , ABCB11 , and ATP8B1 , have been implicated in the pathogenesis of ICP in a number of diff erent studies. Initial studies identifi ed heterozygous mutations of the phosphatidyl choline fl oppase ABCB4 (MDR3) in familial ( 19 ) and sporadic ( 20 ) cases. Homozygous mutations of this gene cause a severe childhood-onset liver disease, PFIC3 ( 21 ) . Th ese fi rst studies of the genetics of ICP susceptibility were confi rmed and expanded by a number of subsequent studies ( 22 -24 ) . Mutations in ABCB4 cause a number of other biliary disorders, including drug-induced cholestasis ( 25 ) and low phospholipid-associated cholelithiasis ( 26 ) . A small single-nucleotide polymorphism (SNP) / haplotype study of common variation around this locus in 52 " severe " ICP cases with serum bile acid levels of > 40 μ M provided additional evidence for a role in ICP susceptibility ( 27 ) . Hence, ABCB4 mutations and variation are linked to a spectrum of cholestatic disease of varying severity. ABCB11 (the bile salt export pump), another member of the ABC transporter superfamily, is the high-affi nity liver-specifi c transporter responsible for the export of conjugated bile acids into the canaliculus ( 28 ) . Homozygous loss-of-function mutations of this gene cause the cholestatic diseases PFIC2 and BRIC2 ( 29 ) . Th e role of genetic variation at this locus in ICP susceptibility has recently been explored in detail, with several recurrent mutations identifi ed, together with the confi rmation of the p.444A variant as a population susceptibility allele ( 30 ) . Further analysis of an Italian cohort has further established ABCB11 variation as playing a role in ICP susceptibility ( 31 ) .
Acting together with ABCB4, this transporter is responsible for bile salt-dependent bile fl ow. Th e phosphatidyl choline fl opped by ABCB4 complexes with bile salts exported by ABCB11 and cholesterol transported by ABCG5 / G8 to form mixed micelles in the canalicular tree and protect the ductal epithelium from the detergent action of the bile salts .
Th e involvement of another familial cholestasis gene, ATP8B1 (mutated in PFIC1 / BRIC1), has not been established defi nitively. Th is protein is proposed to function as a phosphatidyl serine fl ippase in the canalicular membrane and has been studied to a limited extent in ICP cohorts ( 32, 33 ) . Furthermore, recent work has identifi ed a functional interdependence with the ABCB4 protein ( 34 ) .
Bile salt-independent bile fl ow is primarily the result of another transporter, ABCC2 (MRP2 (multidrug resistance-related protein 2)), that transports bilirubin and other organic anions (including some bile acids) across the canalicular membrane ( 35 ) . Involvement of genetic variation around ABCC2 in ICP has been reported in South American populations ( 36 ) .
Th e activity of the transporters responsible for bile formation is regulated by the principal bile acid sensor FXR ( NR1H4 ), and functional variation of this receptor has been identifi ed in ICP ( 37 ) . FXR acts as the master regulator of bile acid homeostasis by sensing intracellular concentrations of bile acids and regulating their metabolism and transport via modulation of promoter activity in key genes ( 38, 39 ) . In addition, key feedback signaling from the gut is performed by fi broblast growth factor 19 ( FGF19 ). Th is is a peptide hormone released by enterocytes via FXR-mediated transcriptional activation. It downregulates hepatocyte CYP7A1 activity (via FGFR4 / β -klotho-mediated transduction) and hence bile acid synthesis ( 40 ) and is vital in controlling appropriate levels of hepatic FXR activity.
In addition to ABCB4 and ABCB11 , these other loci represent biologically plausible candidates for a role in ICP susceptibility. Of note, a number of small studies in a variety of populations have examined other loci postulated to play a role in ICP susceptibility (reviewed in Dixon and Williamson ( 17 ) ) without providing defi nitive evidence of involvement. Although several of the genes have already been demonstrated to play a role in ICP in Caucasians ( ABCB4 , ABCB11 , and NR1H4 ), there is still a paucity of information concerning the contribution of other key genes ( ABCC2 , ATP8B1 , and FGF19 ) in the etiology of ICP.
In order to clarify and expand the genetic factors known to play a role in ICP, we sought to investigate the common variation around the six candidate loci described above in a large ICP cohort and further investigate these fi ndings in a second cohort.
METHODS

Patients (initial cohort )
A cohort of 563 ICP patients of white western European origin together with 642 controls of the same origin from the Rotunda Th rombophilia study ( 41 ) were analyzed in a case -control design. Th is cohort is an extension of our previously described cases (27) and includes all previously studied women. For this study, fasting and nonfasting maternal serum bile acid levels were used to make the diagnosis of ICP as it was not possible to obtain fasting samples from all women attending antenatal clinics.
Th is study conformed to the guidelines outlined by the 1975 Declaration of Helsinki and permission was obtained from the Ethics Committees of the Hammersmith Hospitals NHS Trust, London (REC 97 / 5197), the Ethics Committee of the Faculty of Medicine at the University of G ö teborg, University Hospital Aachen, University Hospital Dusseldorf, and the Ethics committee of the Rotunda Hospital, Dublin.
All ICP patients were diagnosed on the basis of clinical symptoms in combination with routine laboratory investigations, as described previously ( 27, 33 ) . ICP was diagnosed in pregnant women with pruritus without evidence of rash apart from dermatitis artefacta, and confi rmation of the diagnosis was made with raised serum liver transaminases and / or bile acids. Women were excluded if another hepatic disorder was diagnosed following identifi cation of abnormal hepatitis serology (hepatitis A, B, or C), or extrahepatic biliary obstruction following ultrasound examination. Genomic DNA was extracted from buff y coats prepared from EDTA blood samples using standard methods, principally with the Qiagen blood mini kit (Qiagen, Crawley, UK). DNA purity and concentration were determined with an ND-1000 Nanodrop spectrophotometer (Th ermofi sher Scientifi c, Loughborough, UK) .
Polymorphisms around the six candidate loci ( ABCB4 , ABCB11 , NR1H4 , ABCC2 , ATP8B1 , and FGF19) drawn from the HapMap database (version 2, release 22) were analyzed with Haploview (v4.1, Broad Institute, Boston, MA). Markers were selected from the genomic region of each locus including 5 kb up-and downstream of the coding region. Following fi ltering of the marker set to exclude rare alleles (minor allele frequency < 0.05) the tagger algorithm was used to select markers from the HapMap database. Th is identifi ed a set of SNPs that effi ciently captured genetic variation at each locus so that all untyped variants had high correlation ( R 2 > 0.8) with one member of the typed set . In cases where markers had been previously reported to be associated with ICP, these markers were force-included in the selection algorithm.
In total, 83 markers were identifi ed encompassing the six loci as follows: 23 around ABCB11 , 14 around ABCB4 , 11 around ABCC2 , 22 around ATP8B1 , 6 around NR1H4 , and 5 around FGF19 ( Supplementary Table S1 online).
Primers were designed for each selected SNP using " Primer Picker " (KBioscience, Hoddesdon, UK). Genotyping was undertaken using a competitive allele-specifi c PCR SNP genotyping system utilizing FRET quencher cassette oligonucleotides (KASPar, KBioscience) with DNA concentrations adjusted as appropriate.
Statistical analysis
Provided there was no evidence of departure from Hardy -Weinberg equilibrium (Pearson ' s χ 2 test), SNP data were analyzed by Armitage ' s trend test (PLINK v1.07; see ref. ( 42 ) ). Subsequently, the data were tested for a diff erence in haplotype frequencies between cases and controls by χ 2 tests (R v2.10.1, Haplostats V1.4, see ref. ( 43 )) at each locus. All P values were subjected to Bonferroni correction for multiple testing by multiplying uncorrected P values by the number of independent tests performed (78 for SNP testing and 6 for haplotype analysis). Following correction, P values of < 0.05 were considered signifi cant.
Th e association signals were further analyzed using logistic regression performed in R. In particular, we tested each SNP conditional on each other SNP using likelihood ratio tests to determine whether multiple signals were present at each associated loci. Heat maps, in which color indicates the strength of evidence for association, were used to visualize these results.
Second cohort analysis
Th e SNPs identifi ed by this analysis, namely rs2109505 in ABCB4 together with rs7757650 and rs3815676 in ABCB11 , were then tested in a second cohort. Th us, 227 further ICP cases, identifi ed as part of on-going recruitment, were collected in the same way as the fi rst cohort (see above), together with cases from Kings College Hospital (ethics REC 02 / 03 / 033), and DNA extracted and SNP genotyping performed as described above. None of these cases have been reported in our previous genotyping studies.
Association was tested using this cohort alone, and then in a combined analysis of the three SNPs in each cohort, with the statistical tests described above.
RESULTS
In total, 78 markers passed quality control and Hardy -Weinberg testing and were used in association analysis of the two cohorts. Association analysis with the Armitage trend test identifi ed six SNPs in ABCB11 together with six SNPs in ABCB4 showing significant evidence for association ( Table 1 ) . Th e strongest association signals were seen with rs2109505 in ABCB4 and with rs7577650 in ABCB11 . No SNPs from the other four loci showed evidence of association ( Supplementary Table S1 ).
Th e data set was investigated further by haplotype analysis across each of the six loci, which identifi ed signifi cant diff erences in frequencies between cases and controls for ABCB11 and ABCB4. No other signifi cant diff erences in haplotype frequencies across the other loci ( ABCC2 , ATP8B1 , NR1H4 , and FGF19 ) were identifi ed ( Supplementary Table S2 ).
ABCB11
HapMap analysis identifi ed 23 tagging polymorphisms that passed quality control. Association analysis of these markers subsequent to genotyping identifi ed six markers signifi cantly associated with altered risk for ICP: rs228762, rs2058996, rs7605199, rs3815676, rs3814382, and rs7577650 ( Table 1 ) . Th e most strongly associated marker was rs7577650 (trend test corrected P = 1.8 × 10 − 4 ).
ABCB4
HapMap analysis identifi ed 14 polymorphisms that passed quality control. Association analysis of these markers subsequent to genotyping identifi ed six markers signifi cantly associated with altered risk for ICP: rs2097937, rs31676, rs1149222, rs4148826, rs2109505, and rs2302386 ( Table 1 ) . Th e most strongly associated marker was rs2109505 ( P = 4.6 × 10 − 7 ).
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ABCC2 , ATP8B1 , NR1H4 , and FGF19
Around these loci, HapMap analysis identifi ed 41 polymorphisms but none showed signifi cant evidence for association in our cohort ( Supplementary Table S1 ). Th e previously reported ABCC2 association ( 36 ) was not detected in this cohort.
Haplotype analysis
Th e data set was investigated further by haplotype analysis across all six loci ( Supplementary Tables S2 and S3a and b ). Signifi cant diff erences were identifi ed in haplotype distributions between cases and controls for ABCB11 (global corrected P value 0.02) and ABCB4 (global corrected P value 5.76 × 10 − 5 ).
Conditional analysis of association and second cohort analysis
Heat maps were generated using conditional analysis with logistic regression to visualize the patterns of evidence for association across the locus. Th is analysis showed that the association signal in ABCB4 was explained by the SNP rs2109505, with no evidence for further signals (( P > 0.05; Figure 1 ). Th is is shown in the diagram by the red horizontal signal for this SNP (i.e., signifi cant evidence for association regardless of which other SNPs are corrected for) and the white column ( " corrected for " ) for this SNP, indicating no other signifi cant signal when the eff ect of this SNP is corrected for. In contrast, analysis of the associated SNPs in ABCB11 identifi ed evidence for two independent signals, at the SNPs rs3815676 and 7577650: each remains signifi cant ( P < 10 − 4 ) correcting for the other, or any other SNP at this locus ( Figure 2 ). In the heat map, the strong red color again indicates evidence for association, but in this case the " corrected for " column shows evidence of the second signal, indicated by the darker red block. Th e key SNPs identifi ed by this analysis were genotyped in the second cohort. Using the controls from the fi rst cohort for comparison, the association with each SNP was confi rmed and when analyzed together the combined cohort indicated strong evidence for association ( Table 2 ) . Th e odds ratios calculated for the trend tests are allelic and, as ICP is rare, are approximately equivalent to the corresponding relative risk. Th us, for the association with rs3825676 (a rare SNP compared with the majority studied), the odds ratio indicate a risk of ICP that is 3.79 times higher in the homozygote than the heterozygote (with a corresponding reduction in risk in the other homozygote genotype.). For the other SNPs analyzed using this test, the same principle applies. Hence, for the much commoner SNP rs7577650, the homozygotes have a 1.4 times change in risk for ICP, and for rs2109505 in ABCB4 (again a much commoner SNP), the odds ratio shows a change in risk of 2.06-fold.
DISCUSSION
We present here the results of the analysis of six candidate loci for susceptibility to ICP. We have extended and expanded prior studies on these biologically plausible candidates and confi rmed key roles for variation around two of the loci studied by identifying groups of strongly associated polymorphisms. We have demonstrated signifi cant association of SNPs and haplotypes of the key transporters responsible for bile formation, the bile salt export pump ABCB11 , and the phosphatidyl choline fl oppase ABCB4 , with ICP. Aft er determining the key association signals variant rs2109505 (c.711 A > T, p.I237I) was the most signi fi cant, identifi ed as the key signal by conditional analysis and confi rmed in the second cohort. Th is association has been previously reported in smaller population-based studies in ICP ( 22, 27 ) . In silico analysis of splicing using predictive tools together with mini-gene construct mRNA analysis in COS-1 cells failed to identify an eff ect of this variant on ABCB4 splicing (data not shown).
with conditional analysis, these fi ndings were confi rmed in a second cohort. Heterozygous mutant alleles of ABCB4 have been described in a spectrum of cholestatic disease, including ICP ( 17 ) . Our analysis has demonstrated strong association at this locus, confi rming that common polymorphisms together with rare mutations ( 16, 17, 19, 20 ) in this region are implicated in ICP. Of the six polymorphisms showing association, the synonymous 
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Th e contribution of synonymous mutations to disease susceptibility via a number of diff erent mechanisms is being increasingly realized ( 44 ) ; however, the possibility remains that this association is because of linkage disequilibrium between rs2109505 and an unknown causative variant.
Th e association seen at the ABCB11 locus (the bile salt export pump) expands the role of this gene in ICP. We and others previously identifi ed rare heterozygous mutant alleles in ICP, together with an association with rs2287622 (the p.444A polymorphism) ( 30, 45, 46 ) . In this study we have extended the analysis across the gene, and unraveled the genetic architecture underlying susceptibility at this locus. Importantly the association signal in the cases, confi rmed in the expanded cohort with the second group of patients, is composed of two signals, the major one from rs7577650 but with rs3815676 contributing independently to risk, although at a relatively low frequency. Th e p.444A variant remains associated with disease but our comprehensive analysis suggests that a diff erent marker drives this association, namely rs7577650. Th ese FGF19 secretion and signaling represents a key part of the enterohepatic circulation by regulating CYP7A1 expression ( 40 ) , and hence this was a plausible candidate locus for ICP. However, common variation around this locus does not seem to play a major role in disease susceptibility in our cohort.
It is important to recognize however that weaker associations at these other candidate loci may be identifi ed by future studies with much larger cohorts.
In addition to the genetic susceptibility to ICP, evidence is accumulating for the involvement of other factors in this complex condition. During the third trimester when the disease usually presents, circulating levels of reproductive hormones are at their highest and recent work has identifi ed progesterone metabolites as capable of reducing bile acid uptake in hepatocytes, thereby having a potential role in ICP 49 -51) . Estrogen metabolites have also been implicated ( 52 ) . Environmental factors have also been identifi ed that may play a role, including seasonal variation and selenium levels ( 53 ) . A proposed disease mechanism is that altered concentrations of specifi c hormone metabolites can unmask the disease in genetically susceptible individuals.
Th e identifi cation of a role for common variation in ABCB4 and ABCB11 in the etiology of ICP is of relevance in a clinical context. Th e condition has a spectrum of severity. At present, the principal way the severity of maternal disease is classifi ed is in terms of the maternal serum bile acid level. ICP typically presents in the third trimester of pregnancy and resolves aft er delivery of the baby. Approximately 20 % of cases have early-onset disease ( 10 ) and a similar proportion of cases have associated biliary diseases when they are not pregnant, ( 54 ) e.g., cholelithiasis. Although there are studies that demonstrate an association between the level of serum bile acids and rates of adverse pregnancy outcome (8, 10) , the relationships are not straightforward. It will be of value to clinicians managing this condition for future studies to establish whether specifi c genotypes in the mother are associated with an increased risk of specifi c clinical features of ICP, including severity of disease and associated maternal and off spring diseases. Furthermore, patients with ABCB4 mutations respond to ursodeoxycholic acid, and hence it is feasible that the SNPs reported in this study will be associated with treatment response. Th is study was not designed to evaluate treatment response, and hence it was not possible to establish whether this is the case. At present, it is also not known fi ndings have important implications as studies in other populations have postulated roles for the 444A polymorphism in druginduced cholestasis ( 46 ) and in hepatitis C-related cirrhosis ( 47 ) . Given that the SNP rs7577650 is intronic, and that the regression analysis shows it to be driving the association seen with 444A, it is possible that the underlying functional variation has yet to be identifi ed. Deep resequencing of this region using next-generation platforms will be necessary to identify the catalog of variation around the identifi ed associations and identify the underlying causative risk alleles, for both the rs7577650 / 444A signal and the new independent signal we have identifi ed, rs3815676.
Genetic variation around the multidrug resistance-related protein ABCC2 represents an attractive candidate for ICP susceptibility because of the localization and function of the protein ( 35 ) . A previous study of a South American population proposed an association with ICP ( 36 ), but this was not replicated in a European Caucasian population ( 46 ) . By saturating the genomic region of ABCC2 with tagging SNPs in our larger cohort ( n = 563 vs. 70 in the initial report) we have shown that common variation of this transporter does not play a major role in ICP susceptibility in our Caucasian cohort (including the SNP identifi ed in the initial report (rs3740066)).
Th e causative gene for PFIC1 / BRIC1 was also included in our analysis. Previous small studies have reported heterozygous SNPs of ATP8B1 in ICP cases ( 32, 33 ) but have not demonstrated conclusive functional eff ects of these variants in in vitro studies ( 48 ) . Our analysis has excluded common variation around this locus as having a large role in the disease.
We previously identifi ed genetic variation at the NR1H4 (farnesoid-X receptor) locus in our ICP cohort ( 37 ) and demonstrated functional eff ects for some of these variants. However, the population frequencies were very low in both cases and controls. In the expanded cohort used in this study, the frequency of these variants has not changed signifi cantly in cases or controls. Th us, common genetic variation around FXR is unlikely to play a major role in the etiology of ICP. A weakness of this study is that the cohort is not suffi ciently large to identify rare variants that confer susceptibility to ICP, despite being the largest available cohort to our knowledge. Th is is exemplifi ed by the NR1H4 results that confi rmed the presence of rare functional variants but did not establish these variants as common susceptibility alleles for ICP. LIVER ICP and Genetic Variation at Candidate Loci whether mutation screening is justifi ed in ICP. However, with the emerging use of next-generation sequencing technology in the clinic, it will be valuable for future studies to evaluate whether women with early-onset severe disease, particularly if they have a family history of ICP or related biliary disease, have mutations in ABCB4 or ABCB11 . We have identifi ed population risk alleles for ICP in the two genes primarily responsible for bile formation; the phosphatidyl choline fl oppase ABCB4 (MDR3) and the bile salt export pump ABCB11 . Th e identifi cation of the functional variants that underlie these association signals will lead to a greater understanding of the mechanisms responsible for susceptibility to this cholestatic disease of pregnancy.
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